romosozumab

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2018
02420092018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Romosozumab (Romo), a humanized sclerostin antibody, is a bone-forming agent under development for treatment of osteoporosis. To… (More)
  • table 1
  • table 2
Is this relevant?
2017
2017
Romosozumab is a monoclonal antibody that inhibits sclerostin and has been shown to reduce the risk of fractures within 12 months… (More)
Is this relevant?
2017
2017
BACKGROUND Romosozumab is a monoclonal antibody that inhibits sclerostin and rapidly increases bone mineral density (BMD) through… (More)
Is this relevant?
Review
2017
Review
2017
INTRODUCTION Sclerostin, a glycoprotein produced primarily by osteocytes, blocks the canonical Wnt signaling bone formation… (More)
Is this relevant?
Review
2017
Review
2017
Increased understanding of bone biology has led to the discovery of several unique signaling pathways that regulate bone… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2016
2016
Several decades ago, a clinical condition that included severe bone overgrowth was described in a few patients in South Africa… (More)
Is this relevant?
2015
2015
Romosozumab inhibits sclerostin, thereby increasing bone formation and decreasing bone resorption. This dual effect of… (More)
Is this relevant?
Review
2015
Review
2015
In addition to other chronic diseases such as hypertension, hypercholesterolemia, and diabetes, a treat-to-target strategy was… (More)
  • figure 1
Is this relevant?
2014
2014
Romosozumab (formerly AMG 785/CDP7851) is a monoclonal antibody that blocks sclerostin from inhibiting osteoblast maturation and… (More)
Is this relevant?
2014
2014
The Wnt pathway has an important role in bone formation. Inactivation of sclerostin, an inhibitor of this pathway, has been… (More)
Is this relevant?